Therapeutic Prospects of αv Integrins Inhibition in Fibrotic Lung Diseases and Carcinogenesis
International Journal of Molecular Sciences · 27.06.2025 · 26 (13) · 6202
DOI: 10.3390/ijms26136202 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.06.2025. Verfasst von Eugenija Leonidovna Golovina und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk 634050, Russia. Hauptthemen laut MEDLINE: Integrin alphaV, Idiopathic Pulmonary Fibrosis, Lung Neoplasms, Carcinogenesis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The uncontrolled fibrosis of lung tissue can lead to premature death in patients suffering from idiopathic pulmonary fibrosis (IPF), and it complicates the course of chronic obstructive pulmonary disease (COPD) and emphysema. It is also a risk factor for developing lung cancer. Antifibrotic drugs, such as nantedanib and pirfenidone, are able to slow down the progression of pulmonary fibrosis, but more effective treatment is still needed to reverse it. Studies on the pathogenesis of tissue fibrosis have demonstrated that integrins play a crucial role affecting the development of pulmonary fibrosis, for example, by activating transforming growth factor-β (TGF-β). Taking the above into consideration, targeting specific integrins could offer promising opportunities for managing fibroplastic changes in lung tissue. Integrins are a type of transmembrane molecule that mediate interactions between cells and extracellular matrix (ECM) molecules. This review discusses the role of integrins in the pathogeneses of respiratory diseases and carcinogenesis, as well as presents promising approaches to the drug therapy of pulmonary fibrosis of various etiologies based on integrin inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk 634050, Russia.
- Laboratory of Regulation of Reparative Processes, Institute of General Pathology and Pathophysiology, Moscow 125315, Russia.
- Laboratory of Regulation of Reparative Processes, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634050, Russia.
ORCID-Profile: Veronika Vladimirovna Kochubey, Evgenii Germanovich Skurikhin
Zitieren
APA
Golovina, E. L., Kochubey, V. V., Shabanova, M. A., Chekhvalova, D. M., Serebryakova, V. A., Skurikhin, E. G., Vaizova, O. E., Morozov, S. G., Kubatiev, A. A., & Dygai, A. M. (2025). Therapeutic Prospects of αv Integrins Inhibition in Fibrotic Lung Diseases and Carcinogenesis. International Journal of Molecular Sciences, 26(13), 6202. https://doi.org/10.3390/ijms26136202
Vancouver
Golovina EL, Kochubey VV, Shabanova MA, Chekhvalova DM, Serebryakova VA, Skurikhin EG, et al. Therapeutic Prospects of αv Integrins Inhibition in Fibrotic Lung Diseases and Carcinogenesis. International Journal of Molecular Sciences. 2025;26(13):6202. doi:10.3390/ijms26136202
BibTeX
@article{Golovina2025,
author = {Golovina, Eugenija Leonidovna and Kochubey, Veronika Vladimirovna and Shabanova, Marina Alekseevna and Chekhvalova, Darya Maksimovna and Serebryakova, Valentina Alexandrovna and Skurikhin, Evgenii Germanovich and Vaizova, Olga Evgenievna and Morozov, Sergey Georgievich and Kubatiev, Aslan Amirkhanovich and Dygai, Alexander Mikhaylovich},
title = {Therapeutic Prospects of αv Integrins Inhibition in Fibrotic Lung Diseases and Carcinogenesis},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {13},
pages = {6202},
doi = {10.3390/ijms26136202}
}
EUVIMED